Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 46,071,404
  • Shares Outstanding, K 106,290
  • Annual Sales, $ 4,860 M
  • Annual Income, $ 895,520 K
  • 36-Month Beta 1.65
  • Price/Sales 9.48
  • Price/Cash Flow 43.15
  • Price/Book 8.35

Price Performance

See More
Period Period Low Period High Performance
1-Month
426.47 +1.47%
on 09/19/17
505.49 -14.40%
on 09/01/17
-45.93 (-9.60%)
since 08/22/17
3-Month
426.47 +1.47%
on 09/19/17
529.99 -18.35%
on 06/27/17
-93.81 (-17.82%)
since 06/22/17
52-Week
325.35 +33.00%
on 11/04/16
543.55 -20.39%
on 06/22/17
+24.71 (+6.06%)
since 09/22/16

Most Recent Stories

More News
The Medicines Co. Continues to Focus on Pipeline Development

The Medicines Co.'s (MDCO) divestment of non-core assets should allow the company to focus on key assets and brings in a non-dilutive source of funds as well.

MDCO : 35.44 (+1.40%)
MNK : 34.83 (-0.09%)
REGN : 432.72 (-0.17%)
ALXN : 142.82 (-0.07%)
Bayer (BAYRY) Focuses on Pipeline Development & Acquisitions

Bayer (BAYRY) remains focused on developing its pipeline and acquisitions in order to boost its portfolio.

BAYRY : 33.0300 (-0.09%)
REGN : 432.72 (-0.17%)
MON : 119.77 (+0.31%)
ALXN : 142.82 (-0.07%)
Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up

Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.

ALNY : 113.80 (+0.78%)
REGN : 432.72 (-0.17%)
SNY : 50.34 (+0.78%)
ALXN : 142.82 (-0.07%)
How is the Age-Related Macular Degeneration Space Faring Now?

The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.

AGN : 204.65 (+0.98%)
OPHT : 2.69 (unch)
NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
REGN : 432.72 (-0.17%)
ProQR's Genetic Disorder Candidate Gets Orphan Drug Status

ProQR Therapeutics (PRQR) announced that its investigational dystrophic epidermolysis bullosa candidate, QR-313, was granted orphan drug designation by the FDA.

PDLI : 3.17 (-3.06%)
PRQR : 6.20 (+7.83%)
REGN : 432.72 (-0.17%)
ALXN : 142.82 (-0.07%)
Teva/Nuvelution to Speed Up Development of Austedo in US

Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.

HLUYY : 60.1180 (+2.89%)
TEVA : 17.19 (+0.23%)
REGN : 432.72 (-0.17%)
ALXN : 142.82 (-0.07%)
Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia

Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.

JNJ : 131.39 (-0.27%)
REGN : 432.72 (-0.17%)
ALKS : 50.37 (+0.06%)
ALXN : 142.82 (-0.07%)
Pluristem's Ischemia Candidate Gets Fast Track Designation

Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.

PDLI : 3.17 (-3.06%)
REGN : 432.72 (-0.17%)
PSTI : 1.54 (-1.28%)
ALXN : 142.82 (-0.07%)
Zacks.com featured highlights include include Hasbro, Regeneron Pharmaceuticals, Applied Materials, Vantiv, and CBRE Group

Zacks.com featured highlights include include Hasbro, Regeneron Pharmaceuticals, Applied Materials, Vantiv, and CBRE Group

AMAT : 47.77 (+1.31%)
VNTV : 71.93 (-0.24%)
CBG : 37.18 (-0.03%)
HAS : 96.14 (+1.37%)
REGN : 432.72 (-0.17%)
Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU

Glaxo's (GSK) single inhaler triple therapy for the treatment of COPD in patients who are already being treated with a ICS/LAMA combination received a positive opinion from the CHMP in the EU.

INVA : 13.78 (+2.15%)
REGN : 432.72 (-0.17%)
GSK : 40.58 (+0.62%)
ALXN : 142.82 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM....

See More

Support & Resistance

2nd Resistance Point 437.91
1st Resistance Point 435.31
Last Price 432.72
1st Support Level 428.58
2nd Support Level 424.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.